MOTIVATION LETTER The Conjunctive Consolidation Threshold model, a tripartite pharmacological framework for reward-memory encoding prevention, addresses a fundamental gap in addiction neuroscience: no existing therapy directly targets the memory consolidation process that transforms casual drug use into compulsive addiction. My three sole-authored preprints on OSF and Zenodo specify the CCT architecture, its formal mathematical basis, and a Bayesian population dynamics validation showing an 85.8 percent reduction in encoding probability with super-additivity of 12.8 percentage points. All five pre-registered hypotheses H1 through H5 were confirmed. This work has received endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU. A provisional patent on the CCT core architecture is filed for Q3 2026. The UNESCO/Japan Keizo Obuchi Research Fellowships Programme supports exactly this kind of independent, early-career research from LMIC scholars working at the intersection of innovation and sustainable development. My CCT framework is an AI-driven computational pharmacology model that uses ODE/RK45 numerical integration and Bayesian MCMC methods to predict optimal drug combinations for disrupting addiction memory. This aligns directly with the programme's priority themes of Ethical, Inclusive and Human-Centred Artificial Intelligence for Sustainable Development, and AI for Sustainable Cities, Infrastructure and Societal Resilience. Addiction in Nigeria and across sub-Saharan Africa is a growing public health crisis with minimal research investment. My work contributes to UN SDG 3 on Good Health and Well-being by proposing a novel treatment mechanism, and to SDG 9 on Industry, Innovation and Infrastructure by building open-source computational tools including IMPRINT for addiction-liability screening, TOPOLOGIX for topological data analysis of drug-protein interactions, and GATE for BCI neural-stimulation safety evaluation. I hold a B.Pharm from the University of Ibadan with a CGPA of 5.1 out of 7.0, equivalent to a German 1.9, and am a PCN-licensed pharmacist. My independent research output includes a co-authored paper under review at Alcohol and a review article under review at Neuroscience and Biobehavioral Reviews. I am applying for MSc programmes beginning October 2026 at the Medical University of Graz in Austria, and seek a Japanese host supervisor through this fellowship to conduct a six-month to one-year research placement that will advance the CCT model toward preclinical validation. The fellowship's fully funded structure, including travel, living allowance, and research costs, makes this opportunity accessible for an independent researcher based in Lagos. RESEARCH STATEMENT Title: The Conjunctive Consolidation Threshold Model: An AI-Driven Computational Pharmacology Framework for Preventing Addiction Memory Formation in LMIC Populations Background and Rationale Addiction is fundamentally a disorder of pathological memory. The Conjunctive Consolidation Threshold model posits that reward-memory encoding requires three simultaneous conditions: sufficient dopaminergic salience, glutamatergic plasticity permissiveness, and cholinergic gating of hippocampal-striatal circuits. No single existing pharmacotherapy addresses all three nodes simultaneously. The CCT model specifies a tripartite drug combination that reduces encoding probability from 0.855 to 0.122, an 85.8 percent reduction, with super-additivity of 12.8 percentage points beyond additive effects. This was validated using ODE/RK45 numerical integration and Bayesian MCMC population dynamics on simulated neural circuits. Research Objectives Objective 1: Extend the CCT mathematical specification to include pharmacokinetic-pharmacodynamic modeling of the proposed drug combination in a virtual human population. This will use PyMC for Bayesian inference and RDKit for molecular property prediction, incorporating ADMET screening and hERG cardiotoxicity risk assessment via the TOPOLOGIX platform. Objective 2: Validate the CCT model against existing rodent and human addiction datasets. I will apply the model to published intracranial self-stimulation and conditioned place preference data, using Bayesian model comparison to test whether CCT outperforms standard dopamine-only or glutamate-only models. Objective 3: Design a Phase I clinical trial architecture for the CCT combination in a Nigerian clinical population, incorporating the Bayesian adaptive randomization framework specified in my Zenodo preprint. This trial will target alcohol use disorder, the most prevalent substance use disorder in Nigeria. Methodology The research will be conducted in collaboration with a Japanese host laboratory specializing in computational neuroscience or addiction pharmacology. I will use Python with scipy, numpy, and PyMC for all modeling; NEURON and Brian2 for spiking neural network simulations; and the TOPOLOGIX platform for topological data analysis of drug-protein interaction networks. All code will be released under Apache 2.0 licenses on GitHub. Expected Outcomes and Impact The primary outcome is a validated, publication-ready computational framework for designing addiction pharmacotherapies. Secondary outcomes include a clinical trial protocol ready for ethics submission and an open-source software suite for addiction-liability screening. For Nigeria and other LMICs, where addiction treatment access is below 10 percent, this work provides a low-cost, computationally guided pathway to novel therapies without requiring expensive wet-lab infrastructure. Relevance to UNESCO/Japan Programme This research directly addresses the programme's priority on Ethical, Inclusive and Human-Centred Artificial Intelligence for Sustainable Development. The CCT model uses AI not to replace human judgment but to optimize pharmacological interventions that preserve patient autonomy and reduce harm. The open-source, reproducible framework ensures accessibility for researchers in resource-limited settings. SHORT ESSAY: RELEVANCE TO UNESCO PRIORITY AREAS The CCT model contributes to three UNESCO priority areas. First, under Ethical, Inclusive and Human-Centred Artificial Intelligence for Sustainable Development, the model uses Bayesian inference and numerical simulation to design pharmacological interventions that are transparent, interpretable, and grounded in established neuroscience. The code is open-source under Apache 2.0, and all preprints are on OSF and Zenodo with DOIs. This ensures that researchers in any country, including Nigeria, can reproduce and extend the work without proprietary software or expensive licenses. Second, under AI for Sustainable Cities, Infrastructure and Societal Resilience, addiction is a driver of urban poverty, crime, and family breakdown. In Lagos, a city of over 20 million people, substance use disorder prevalence is rising with no coordinated treatment infrastructure. The CCT model provides a computationally efficient method for screening drug combinations before clinical trials, reducing the cost and time of bringing new treatments to underserved populations. Third, the work supports UN SDG 3 on Good Health and Well-being by targeting a disease that kills over 600,000 people annually in sub-Saharan Africa through alcohol-related causes alone. It supports SDG 9 on Industry, Innovation and Infrastructure by building computational tools that can be deployed on modest hardware, making advanced pharmacology research accessible to Nigerian universities and research institutes. SHORT ESSAY: RESEARCH POTENTIAL AND EARLY-CAREER TRAJECTORY My research trajectory demonstrates exceptional independence and originality for a pre-PhD researcher. Between 2025 and 2026, I conceived, mathematically specified, computationally validated, and publicly disseminated the CCT model entirely as an independent researcher with no institutional affiliation. The three preprints on OSF and Zenodo represent a complete research cycle: theoretical foundation, formal mathematical specification, and Bayesian validation with clinical trial architecture. A review article is under review at Neuroscience and Biobehavioral Reviews, and a co-authored paper is under review at Alcohol. The endorsements from Kent Berridge, Samuel Gershman, Nathaniel Daw, and Marcelo Mattar confirm that my work meets the standards of leading computational neuroscience laboratories. Samuel Gershman provided an arXiv endorsement, a formal recognition of research quality. The provisional patent on the CCT core architecture filed in Q3 2026 demonstrates that the work has commercial and clinical translation potential. My technical skills span computational pharmacology, topological data analysis, Bayesian statistics, and neural simulation. I have built three functional platforms: IMPRINT for addiction-liability screening, TOPOLOGIX for drug-protein interaction analysis using persistent homology and bipartite simplicial complexes, and GATE for BCI neural-stimulation safety evaluation. These platforms are deployed on GitHub and zyco.org. The UNESCO/Japan fellowship is the ideal next step. It will provide the structured mentorship, Japanese host laboratory collaboration, and funding needed to transition from independent research to formal PhD training. My MSc application for October 2026 at the Medical University of Graz in Austria will complement the fellowship by providing formal coursework in computational neuroscience. CHECKLIST - [ ] Completed UNESCO/Japan Young Researchers' Fellowships Programme 2026 application form - [ ] Motivation letter (this document) - [ ] Research statement (this document) - [ ] Short essay on relevance to UNESCO priority areas (this document) - [ ] Short essay on research potential and early-career trajectory (this document) - [ ] Curriculum vitae with full publication list and ORCID - [ ] Certified copies of B.Pharm degree certificate and academic transcripts - [ ] PCN pharmacist license copy - [ ] Two letters of recommendation (suggested: Kent Berridge or Samuel Gershman, and one academic referee from University of Ibadan) - [ ] Acceptance letter from a Japanese academic supervisor (mandatory prerequisite) - [ ] Research proposal in the format specified by the host Japanese institution - [ ] Proof of English proficiency (if required by host institution) - [ ] Copy of passport biodata page - [ ] Passport-sized photographs - [ ] Completed UNESCO fellowship agreement form EDITOR NOTES - Eligibility risk: The programme requires an acceptance letter from a Japanese academic supervisor. Eniola has no listed Japanese collaborators. He must identify and contact potential host laboratories in Japan immediately. Suggested targets: RIKEN Center for Brain Science, Kyoto University Department of Pharmacology, University of Tokyo Graduate School of Pharmaceutical Sciences. - Fact verification: The programme deadline is listed as "see programme website." The provided URL is an aggregator, not the official UNESCO page. Eniola must locate the official UNESCO/Japan Keizo Obuchi Research Fellowships page to confirm deadline, eligibility, and required documents. - Gap in profile: Eniola's age (29) may approach the upper limit for "young researchers" programmes. The official UNESCO page should specify the age cutoff. If it is 30 or 35, he is eligible. If it is 25, he may need to argue for an exception based on his independent research output. - Missing detail: The application requires a specific research plan for the Japan placement period. Eniola must draft a 6-12 month timeline with milestones, deliverables, and host laboratory resources needed. This should be added to the research statement. - Language proficiency: If the host institution requires Japanese language proficiency, Eniola has no listed Japanese language skills. He should confirm whether English-taught programmes are available at his target host laboratory.